A decision is expected in the fourth quarter of 2025.

Children and young adults living in states with the biggest drops in Medicaid coverage experienced more prescription ...

High costs and the novelty and complexity of new therapies such as gene therapy present social determinants of health and ...

Cost is a barrier to care for chronic and rare diseases, so financial assistance is way to lower that barrier and help people ...

A new study by JAMA Health Forum found that universal annual depression screening for young adults during primary care visits ...

In January 2023, the Brukinsa, a next-generation BTK inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL).

Cigna Healthcare’s medical care ratio increased to 82.2% in the first quarter compared with 79.9% in the first quarter of ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

In mice with human Merkel cell carcinoma, pyrvinium pamoate significantly reduced tumor growth, potentially offering a new ...

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Kathi Henson, senior vice president of patient services, nursing and quality at Orsini, spoke with MHE editors at this year’s ...

Payers and providers, often depicted as rivals, are on the same side when it comes to the 340B program that allows some ...